Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Home  /  Forum  /  MDxHealth  /  MDxHealth's PredictMDx for Glioblastoma Identifies Newly Diagnose

Ontvang nu dagelijks onze kooptips!

word abonnee

MDxHealth's PredictMDx for Glioblastoma Identifies Newly Diagnose

8 Posts
| Omlaag ↓
  1. [verwijderd] 4 maart 2014 08:20
    Buy and Hold

    Published: 08:00 CET 04-03-2014 /GlobeNewswire /Source: MDxHealth (TM) /XBRU: MDXH /ISIN: BE0003844611

    MDxHealth's PredictMDx for Glioblastoma Identifies Newly Diagnosed Patients with Improved Progression Free and Overall Survival

    Results of Phase III Trial for Bevacizumab (Avastin®) Published in
    the New England Journal of Medicine

    IRVINE, California, and HERSTAL, BELGIUM - March 4, 2014 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that the publication in the New England Journal of Medicine of a phase III randomized trial of bevacizumab, brand name Avastin®, for newly diagnosed glioblastoma patients, confirms the clinical utility of its PredictMDx® for Glioblastoma test.

    MDxHealth's PredictMDx for Glioblastoma (MGMT) test, included in the 2013 National Comprehensive Cancer Network (NCCN) Senior Adult Oncology Guidelines, provides actionable information to oncologists seeking to provide personalized treatment of elderly patients with glioblastoma (GBM), the most common and most aggressive malignant primary brain tumor in humans. The test assesses the methylation status of the MGMT gene, which is a key DNA repair component. If the MGMT gene is methylated, cancer patients have shown improved response to alkylating drug therapy. Studies on thousands of clinical trial patients have demonstrated that PredictMDx for Glioblastoma can help oncologists identify newly diagnosed glioblastoma patients that are likely to respond to the most commonly used class of brain cancer drugs (alkylating agents).

    Dr Gilbert et al describe the results of the phase III study, "A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma" (N Engl J Med 2014; 370:699-708, February 20, 2014) in which patients were prospectively randomized into the treatment arms based on MDxHealth's MGMT (O6-methylguanine-DNA methyl transferase) methylation test results. MGMT methylation status was shown to be prognostic for progression-free survival (PFS) and overall survival (OS), regardless of therapies investigated in this study. The median PFS for patients with unmethylated tumors was 8.2 months vs. 14.1 months in the patients with MGMT methylated tumors, with a hazard ratio of 1.67 (95% CI of 1.36 to 2.05, p<0.001). The median OS for patients with MGMT unmethylated tumors was 14.3 months compared with 23.2 months in patients with MGMT methylated tumors. The hazard ratio for death in patients with unmethylated tumors was reported as 2.10 (95% CI of 1.65 to 2.68, p<0.001).

    "As shown in previous published studies these results again confirm the prognostic value of our PredictMDx test in glioblastoma. These results demonstrate the clinical importance of using molecular biomarkers, like MGMT, to improve patient stratification and the current standard of care," stated Prof. Dr. Wim van Criekinge, Chief Scientific Officer of MDxHealth.

    About MDxHealth®

    MDxHealth (formerly OncoMethylome Sciences) is a molecular diagnostics company that develops and commercializes advanced epigenetic tests for cancer assessment and the personalized treatment of patients. The company's first commercial product, ConfirmMDx® for Prostate Cancer, has been validated to help distinguish patients who have a true-negative biopsy from those who may have undetected cancer, thereby aiding in the reduction of unnecessary repeat biopsies. MDxHealth helps to address a large and growing unmet medical need for better cancer diagnosis and treatment information. The company has a proprietary platform and a strong epigenetic product pipeline focused on the development of products for prostate, brain, bladder and lung cancers. For more information visit www.mdxhealth.com and follow us on Twitter at: twitter.com/mdxhealth.

    For more information:

    Dr. Jan Groen, CEO
    Mike Sinclair (media)
    Len Hall (investors)
    MDxHealth
    Halsin Partners
    Allen & Caron, Inc
    US: +1 949 812 6979
    UK: +44 20 7318 2955
    US: +1 949 474 4300
    BE: +32 4 364 20 70
    Cell:+44 7968 022075
    len@allencaron.com
    info@mdxhealth.com
    msinclair@halsin.com

    This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company's control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.

    NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx and PredictMDx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.

    To access the PDF version, please click here

    This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients. Source: MDxHealth (TM), Tour 5 GIGA niveau +3 Av. de l’Hopital 11, Liège 4000, Belgique
    If you would like to unsubscribe and stop receiving these e-mails click here.
  6. [verwijderd] 4 maart 2015 15:28
    quote:

    bioscience schreef op 4 maart 2014 09:26:

    Wat mij opvalt is dat er veel kt denkers zitten in MDx .

    Dit is volgens mij een aandeel voor de LT met zeer grote mogelijkheden . Nu kopen en een aantal jaren vasthouden .

    Zodra er meer LT beleggers ingaan , wordt het aandeel ook een stuk stabieler .Kwestie van tijd .
    B.A.H.
    Wat is het uithoudingsvermogen van een LT belegger 3,5,7 of 10 of 30 jaar:-)?
    10 jaar vanaf nu vind ik mooi zat. Liever 5.
8 Posts
|Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!

Word abonnee

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!